Skip to main content

Select Drug Profiles

FDA Approvals, Select Drug Profiles

FDA Approves First Prostate-Specific Membrane Antigen–Targeted PET Imaging Drug for Prostate Cancer

FDA Approvals, Leukemia, Select Drug Profiles

Oral Onureg First Drug Approved for Adults with AML in Remission

FDA Approvals, Select Drug Profiles

Danyelza Receives FDA Approval for High-Risk Neuroblastoma in the Bone and Bone Marrow

FDA Approvals, Select Drug Profiles

Gavreto, a New RET Inhibitor, Now Approved for Thyroid Cancer with RET Fusions

FDA Approvals, Select Drug Profiles

Opdivo Approved for Advanced Esophageal Squamous-Cell Carcinoma

FDA Approvals, Lung Cancer, Select Drug Profiles

FDA Approves Cyramza plus Tarceva for First-Line Treatment of Metastatic NSCLC with EGFR Mutation

FDA Approvals, Lung Cancer, Select Drug Profiles

Opdivo plus Yervoy and Limited Chemotherapy Approved as First-Line Therapy for Metastatic NSCLC, Regardless of PD-L1 Expression

FDA Approvals, Lung Cancer, Select Drug Profiles

Tecentriq plus Avastin First Immunotherapy Regimen Approved for Metastatic Hepatocellular Carcinoma

FDA Approvals, Prostate Cancer, Select Drug Profiles

Lynparza First Targeted Therapy Approved for Metastatic Prostate Cancer with HRR Mutation

FDA Approvals, Lung Cancer, Select Drug Profiles

Tecentriq Approved as First-Line Therapy for Metastatic NSCLC with High PD-L1 Expression

1
2
3
4
5
6

Page 3 of 20
Results 21 - 30 of 200